Compugen Ltd. (CGEN)
 NASDAQ: CGEN · Real-Time Price · USD
 1.650
 0.00 (0.00%)
  At close: Oct 30, 2025, 4:00 PM EDT
1.670
 +0.020 (1.21%)
  After-hours: Oct 30, 2025, 7:57 PM EDT
Compugen Revenue
Compugen had revenue of $1.26M in the quarter ending June 30, 2025, a decrease of -81.24%. This brings the company's revenue in the last twelve months to $22.14M, down -48.16% year-over-year. In the year 2024, Compugen had annual revenue of $27.86M, down -16.72%.
Revenue (ttm) 
 $22.14M
Revenue Growth 
 -48.16%
P/S Ratio 
 6.80
Revenue / Employee 
 $299,243
Employees 
 74
Market Cap 
154.33M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth | 
|---|---|---|---|
| Dec 31, 2024 | 27.86M | -5.60M | -16.72% | 
| Dec 31, 2023 | 33.46M | 25.96M | 346.12% | 
| Dec 31, 2022 | 7.50M | 1.50M | 25.00% | 
| Dec 31, 2021 | 6.00M | 4.00M | 200.00% | 
| Dec 31, 2020 | 2.00M | - | - | 
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue | 
|---|---|
| UnitedHealth Group | 435.16B | 
| Johnson & Johnson | 92.15B | 
| Merck & Co. | 63.62B | 
| AbbVie | 58.33B | 
| AstraZeneca | 56.50B | 
| Novartis AG | 56.37B | 
| Eli Lilly and Company | 53.26B | 
| Novo Nordisk | 49.11B | 
CGEN News
- 3 days ago - Compugen to Release Third Quarter 2025 Results on Monday, November 10, 2025 - PRNewsWire
- 17 days ago - Compugen to Present Pooled Analysis of COM701 in Three Phase 1 Trials in Patients with Platinum Resistant Ovarian Cancer at ESMO 2025 - PRNewsWire
- 24 days ago - Compugen to Present at SITC 2025 - PRNewsWire
- 7 weeks ago - Compugen to Present Research at the Single Cell Genomics 2025 Conference - PRNewsWire
- 2 months ago - Compugen to Present at the H.C. Wainwright 27th Annual Global Investment Conference - PRNewsWire
- 2 months ago - Compugen: Potential Best-In-Class Anti-PVRIG COM701 Shifts To Targeting PSOC Patients - Seeking Alpha
- 3 months ago - Compugen Ltd. (CGEN) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Compugen Reports Second Quarter 2025 Results - PRNewsWire